Search results
When do you need to start getting a mammogram? Here's what new recommendations say.
Yahoo Life· 16 hours ago“There is also literature that has shown that the rate of breast cancer among women ages 40 to 49...
Study highlights increased risk of second cancers among breast cancer survivors
Medical Xpress· 6 days agoSurvivors of breast cancer are at significantly higher risk of developing secondcancers, including...
Cancer survivors from poorer places at higher risk of second cancer
KTBS Shreveport· 6 days agoBreast cancer survivors from more deprived areas are at a far higher risk of developing a second ...
Could Vitamin D Help Fight Cancer?
Mercola· 3 hours agoIn this way, vitamin D acts like a brake on the process of cell growth in many tissues of the body, helping to control the speed at which cells multiply. This is particularly important when ...
Column: My Mami's hard life, cut short right when it was about to get really good
LA Times via Yahoo News· 3 days agoDoctors dismissed her initial complaints about abdominal pains as nothing to worry about until one...
...Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as...
Morningstar· 7 days agoResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 ...
AbbVie Reports First-Quarter 2024 Financial Results
The Belmond Independent· 5 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society...
Morningstar· 7 days ago– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMFORD
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation...
Digital Journal· 7 days agoThe primary objectives of the trial include determining the maximum tolerated dose and/or recommended Phase 2 dose and evaluating antitumor activity of tulmimetostat monotherapy...
